Oric Pharmaceuticals (ORIC) AI Stock Analysis

• Market Cap: $1.35B
• Dividend Yield: N/A
• Average Volume (3M): 1.48M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: N/A
• EPS Growth: 4.29%
• Country: US
• Employees: 122
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 100,358,240
• 10 Day Avg. Volume: 867,661
• 30 Day Avg. Volume: 1,484,300
• PEG Ratio: 0.28
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.30
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.97K
• Enterprise Value/Ebitda: -9.51
• 1Y Price Target: $20.70
• Price Target Upside: 54.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -1.44
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $14.00 ▲(4.48% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is driven primarily by mixed financial fundamentals—strong liquidity/low leverage but no revenue and ongoing losses with sustained cash burn. Technicals are supportive (uptrend with positive MACD) but look overextended (RSI/Stoch), while valuation remains constrained by negative earnings and no dividend. A positive clinical-trial corporate update provides an additional, but secondary, tailwind.

Positive Factors

Strong balance sheet & low debt

A balance sheet with minimal leverage, positive equity and materially higher total assets improves durable funding capacity. That structural liquidity gives management flexibility to advance clinical programs, negotiate partnerships, and withstand development volatility without immediate cash-flow dependence on product revenues.

Promising enozertinib clinical data

Phase 1b signals of systemic and intracranial activity with manageable safety for enozertinib suggest a potential differentiated oncology asset. If confirmed, a best-in-class profile addressing EGFR-mutated NSCLC could underpin sustainable commercial revenue, partner interest, and long-term enterprise value versus peers.

Established ATM financing program

An active at-the-market equity facility provides a structural tool to access capital incrementally. For a clinical-stage biotech with no product cashflows, this durable financing flexibility reduces reliance on single large financings, enabling staged funding of trials and strategic dealmaking while smoothing liquidity management.

Negative Factors

No revenue and widening losses

Absence of product revenue combined with growing net losses is a persistent structural weakness: it necessitates continual external funding, erodes equity over time, and constrains reinvestment optionality. Persistent losses limit self-sufficiency and increase strategic pressure on management to monetize programs or cut costs.

Sustained negative free cash flow

Consistent negative operating and free cash flow, and rising cash burn, shorten runway and raise structural financing requirements. This dynamic forces recurring capital raises or partnerships, which can dilute shareholders or constrain negotiating leverage and may force tradeoffs in R&D prioritization.

Clinical-stage, binary pipeline risk

Being wholly development-stage means company value hinges on trial outcomes and regulatory decisions. This binary risk is durable: programs can fail, timelines slip, or show limited commercial differentiation. Dependence on clinical success increases volatility in cash generation and long-term viability absent partnering or approvals.

Oric Pharmaceuticals Business Overview & Revenue Model

Company Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

How the Company Makes Money

Oric Pharmaceuticals generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to monetize its pipeline by advancing its proprietary compounds through clinical trials and obtaining regulatory approval, which then allows it to either market these drugs directly or license them to larger pharmaceutical companies. Key revenue streams include potential milestone payments, royalties from partnerships with larger pharmaceutical companies, and future product sales upon successful drug approval. Oric may also engage in strategic collaborations and partnerships to co-develop or out-license its technologies, which can provide upfront payments and shared development costs, contributing to its revenue.

Oric Pharmaceuticals Financial Statement Overview

Summary

Financial profile is mixed: a strong, low-debt balance sheet (positive equity and rising total assets) supports funding capacity, but it is offset by no revenue, widening net losses, and persistent negative free cash flow with continued cash burn.

Income Statement

The income statement remains weak, with no reported revenue across the period and consistently large operating losses. Losses have generally widened versus earlier years (net loss roughly -$74M in 2020 to about -$129M in 2025), indicating a higher spend profile. A modest positive is that results appear relatively consistent year-to-year for a development-stage biotech, but the absence of revenue and persistent negative profitability are the primary constraints.

Balance Sheet

The balance sheet is a clear strength: the company operates with minimal to no debt (debt-to-equity near zero in most years) and maintains positive equity. Total assets increased meaningfully into 2025 (about $409M vs. ~$274M in 2024), supporting liquidity and funding capacity. The key weakness is ongoing negative returns on equity in prior years (driven by net losses), which can pressure the capital base over time if losses persist.

Cash Flow

Cash flow is pressured by sustained cash burn: operating cash flow and free cash flow are negative every year shown (around -$111M in 2025). Free cash flow deterioration in 2025 versus 2024 suggests burn may be rising rather than stabilizing. A relative positive is that free cash flow broadly tracks net loss (cash usage roughly in line with accounting losses), but the overall profile still indicates ongoing funding needs until revenue ramps.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.22M	-1.11M	-1.03M	0.00	0.00
EBITDA	-128.25M	-126.74M	-109.75M	-85.80M	-77.97M
Net Income	-129.47M	-127.85M	-100.70M	-89.12M	-78.72M
Balance Sheet
Total Assets	411.00M	274.14M	254.69M	250.36M	298.64M
Cash, Cash Equivalents and Short-Term Investments	281.49M	255.96M	208.19M	206.27M	236.98M
Total Debt	11.55M	3.18M	10.21M	12.10M	1.93M
Total Liabilities	26.64M	31.02M	30.60M	28.01M	25.67M
Stockholders Equity	384.36M	243.12M	224.09M	222.35M	272.98M
Cash Flow
Free Cash Flow	-114.08M	-113.85M	-86.54M	-77.22M	-60.48M
Operating Cash Flow	-113.37M	-112.66M	-85.69M	-75.14M	-59.54M
Investing Cash Flow	-148.03M	22.14M	-43.40M	-109.25M	158.44M
Financing Cash Flow	245.26M	126.55M	85.66M	25.23M	49.13M

Oric Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Positive. The current price of 13.4 is above the 20-day moving average (MA) of 10.94, above the 50-day MA of 10.12, and above the 200-day MA of 10.42, indicating a bullish trend. The MACD of 0.51 indicates Negative momentum. The RSI at 70.29 is Negative, neither overbought nor oversold. The STOCH value of 86.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORIC.

Oric Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRAX	67 Neutral	$9.54B	-25.81	-45.83%	―	364.98%	-25.33%
SYRE	59 Neutral	$3.41B	-21.12	-22.03%	―	―	-123.65%
PHAR	58 Neutral	$1.19B	1,166.67	0.44%	―	26.54%	―
ORIC	57 Neutral	$1.35B	-8.85	-41.27%	―	―	4.29%
TRVI	57 Neutral	$1.45B	-30.60	-36.87%	―	―	15.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRME	50 Neutral	$691.36M	-2.80	-112.34%	―	647.13%	26.79%

Oric Pharmaceuticals Corporate Events

Oric Pharmaceuticals Launches New 2026 ATM Share Program

On May 6, 2021, ORIC Pharmaceuticals, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell common shares through an at-the-market offering program, using Jefferies as sales agent under an effective shelf registration filed on March 11, 2024. Under a 2024 prospectus supplement tied to this agreement, the company sold 13,478,432 shares for gross proceeds of about $139.7 million as of February 23, 2026, and on February 26, 2026, it transitioned to a new 2026 prospectus supplement for up to $200 million in additional share sales, with no further issuances to occur under the 2024 supplement.

The most recent analyst rating on (ORIC) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.

Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results

On December 6, 2025, Oric Pharmaceuticals presented an update on its enozertinib (ORIC-114) program, highlighting data from a Phase 1b trial. The update revealed that enozertinib shows promising systemic and intracranial activity in EGFR-mutated NSCLC, potentially establishing a best-in-class profile. With no significant off-target toxicity and a manageable safety profile, enozertinib could address a significant commercial opportunity in the U.S., estimated at $3.0 to $3.5 billion annually, targeting approximately 9,000 patients with NSCLC.

The most recent analyst rating on (ORIC) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.